aTYR PHARMA (ATYR) Profit After Tax (2014 - 2026)

aTYR PHARMA (ATYR) has 13 years of Profit After Tax data on file, last reported at -$10.8 million in Q1 2026.

• Quarterly Profit After Tax rose 27.42% year-over-year to -$10.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$70.0 million (down 10.45% YoY) and the FY2025 annual result came in at -$74.1 million, down 15.78% from the prior year.
• Profit After Tax improved to -$10.8 million in Q1 2026, from -$14.0 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$7.5 million in Q4 2022 to a low of -$25.7 million in Q3 2025.
• A 5-year average of -$14.4 million and a median of -$14.0 million in 2025 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax plunged 96.3% — and 2026, when it increased 27.42%.
• Tracing ATYR's Profit After Tax over 5 years: stood at -$7.5 million in 2022, then plunged by 96.3% to -$14.8 million in 2023, then declined by 1.36% to -$15.0 million in 2024, then increased by 6.69% to -$14.0 million in 2025, then rose by 22.68% to -$10.8 million in 2026.
• The last three Profit After Tax figures came in at -$10.8 million (Q1 2026), -$14.0 million (Q4 2025), and -$25.7 million (Q3 2025), per Business Quant data.